ReviewMolecular biology reports2026
Harnessing flavonoids as innovative agents for the modulation of platelet activation and thrombotic disorders.
Review in Molecular biology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Thrombotic diseases remain a leading cause of global mortality and a significant public health burden. While conventional antiplatelet and anticoagulant therapies are cornerstone strategies, their clinical application is frequently hindered by a significant risk of hemorrhagic complications and limited efficacy in certain patient populations. Consequently, there is an urgent need for safer and more effective antithrombotic agents. Flavonoids, a diverse class of plant-derived polyphenols, have garnered considerable attention due to their potent antiplatelet and antithrombotic activities coupled with a favorable safety profile. This review systematically examines the latest advancements in the therapeutic effects of flavonoids on thromboembolic disorders and elucidates their underlying molecular mechanisms. Evidence suggests that flavonoids function as multi-target inhibitors. They exert antithrombotic effects by regulating platelet activation through interfering with multiple signaling pathways, including the ADP-mediated P2Y1/P2Y12 cascade, cyclic nucleotide (cAMP/cGMP) signaling, and the collagen pathway. Additionally, these compounds inhibit the coagulation cascade by targeting key proteases including thrombin. This review provides an evidence-based roadmap for the development of flavonoid-derived therapies, aiming to facilitate their translation into clinical interventions for the effective management of thrombotic diseases.
Indexed as
Identifiers
42397528What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.